CorMedix went into this print with a value story and a low P/E multiple that had already caught investor attention. The stock still dropped 7.4% to close near US$7.54 after the report. This suggests that emotion is running ahead of the headline numbers.

The quarter itself was not a collapse story. CorMedix posted Q2 revenue of US$101.9m and net income of US$25.8m, and management raised full year adjusted EBITDA guidance to a range of US$125m to US$140m. That creates a clear expectation gap for investors to unpack in the rest of this earnings breakdown.

Is CorMedix at a P/E of 3.2x a genuine mispricing, or a value trap that the earnings forecasts already capture? Compare the current market price against fair value in our valuation analysis for CorMedix

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs Q2 2025: US$101.9m vs US$39.7m (very large year over year increase, helped by the Melinta acquisition)
• Net Income, Q2 2026 vs Q2 2025: US$25.8m vs US$19.7m (up about 31% year over year)
• Basic EPS, Q2 2026 vs Q2 2025: US$0.33 vs US$0.29 (up about 13% year over year)
• Products Approved, Q2 2026 vs Q2 2025: 1 vs 0 (CorMedix now reporting one approved product in the period)

Prefer clear visuals instead of scrolling through another dense earnings breakdown? See CorMedix's full financial picture, with a focus on valuation, in an easy chart-based format in our company report for CorMedix.

CorMedix bull case leans on cash and contracts

Bulls argue CorMedix is building a durable anti infective platform around DefenCath and Melinta, with cash generation that supports growth projects without dilution. Q2 numbers give that view some concrete wins. Revenue reached US$101.9m with adjusted EBITDA at US$58.7m and net income at US$26.0m, which aligns with management lifting full year EBITDA guidance to US$125m to US$140m. Cash and equivalents of US$256.7m and year to date operating cash flow of US$128.6m back the claim of self funded development. On execution, CorMedix has now contracted with all five top U.S. dialysis providers and secured a new large dialysis organization pilot that management says fits within guidance. Positive Phase III ReSPECT data for REZZAYO and a planned sNDA (a supplemental New Drug Application) in Q3 2026 move the "next growth leg" from story to dated milestone.

Bear case focuses on concentration, costs and stock reaction

The bear narrative centers on concentrated dialysis exposure, cost absorption after Melinta, and financing and legal overhangs. Q2 results soften some of that but do not remove it. Management reports DefenCath utilization as stable at large customers, with attrition in very small providers, which partially addresses customer loss fears yet still confirms sensitivity around the edges. Operating costs stepped up with R&D at US$6.7m, sales and marketing at US$12.4m, and G&A at US$15.1m even with a US$4.2m insurance credit, so the burden of proving longer term margin resilience remains. The stock fell 7.4% on the print and is down about 10% over 30 days, which shows investors are not treating raised EBITDA guidance as a free pass on execution or on risks around TDAPA reimbursement changes, convertible debt maturity, and ongoing litigation.

After a 7.4% share price drop, rising costs and pressure on earnings forecasts raise a larger question. Review our independent risk analysis for CorMedix which shows 1 important warning sign

Stay Ahead With Simply Wall St

With CorMedix trading on a low P/E and the stock falling 7.4% after earnings, it can help to track how sentiment and valuation move from here rather than react to every headline. Register for free with Simply Wall St and add CorMedix to your Watchlist to watch price against fair value and look for a better entry or add point. Once you are invested, use the Portfolio Command Center to keep your holdings organised and surface only the updates that really matter. Over the longer term, compare your thinking with thousands of other investors through the Community so you can spot potential catalysts or emerging risks early and stay ahead of the market.

Curious About Alternatives Worth Exploring

Fresh stock ideas can move from quiet build up to breakout before most investors even notice. Scan these curated lists while the data still matters and get in early.

• Spot companies with strong fundamentals that the crowd has not fully caught yet through a curated 18 high quality undiscovered gems and position your watchlist before momentum starts building.
• Track infrastructure players that could gain from rising AI demand using a focused 55 AI infrastructure stocks. This can help you line up potential entries while they remain less widely followed for now.
• Find producers that could benefit if gold sentiment turns and money rotates back into hard assets with a hand picked 30 elite gold producer stocks. This may allow you to act before any significant price moves occur.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.